האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - c-hepatiit, krooniline - viirusevastased ravimid süsteemseks kasutamiseks - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (vt punktid 4. 2, 4. 4 ja 5.

האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - antineoplastilised ained - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.

האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

pierre fabre medicament - binimetinib - melanoom - antineoplastilised ained - binimetinib koos encorafenib on näidustatud ravi täiskasvanud patsientidel, kellel unresectable või metastaatiline melanoom, mille braf v600 mutatsioon.

האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

lipomed gmbh - deferiprone - iron overload; beta-thalassemia - kõik muud ravitoimingud - deferiprone lipomed monotherapy on näidustatud ravi raua ülekoormusega patsientidel thalassaemia suur kui praegune kelaatio ravi on vastunäidustatud või ebapiisav. deferiprone lipomed koos teise chelator on näidustatud patsientidel, kellel thalassaemia suur, kui monotherapy mis tahes raud chelator on ebaefektiivne, või kui vältimiseks või raviks eluohtlikud tagajärjed raua ülekoormuse õigustab kiire või intensiivse parandus.

האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastilised ained - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastilised ained - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - muud alimentary seedetrakti ja ainevahetust tooted, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - immunosupressandid - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).